10-K/A Filing

BNB PLUS CORP. CIK: 744452 FY 2021

Filing Information

Form Type	10-K/A
Accession Number	`0001410578-21-000536`
Period End Date	20210930
Filing Date	20211214
Fiscal Year	2021
Fiscal Period	FY
XBRL Instance	apdn-20210930x10ka_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 70 Income Statement 43 Cash Flow Statement 71 Stockholders Equity 19

Balance Sheet 70 line items

Line Item	Tag	Value	Unit	Period
Allowance on accounts receivable (in dollars)	`AllowanceForDoubtfulAccountsReceivableCurrent`	$29.82K	USD	Point-in-time
Allowance on accounts receivable (in dollars)	`AllowanceForDoubtfulAccountsReceivableCurrent`	$11.97K	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.79M	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$6.55M	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Accounts receivable, net of allowance of $29,821 and $11,968 at September 30, 2021 and 2020, respectively	`AccountsReceivableNetCurrent`	$2.80M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Accounts receivable, net of allowance of $29,821 and $11,968 at September 30, 2021 and 2020, respectively	`AccountsReceivableNetCurrent`	$194.32K	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Inventories	`InventoryNet`	$1.37M	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Inventories	`InventoryNet`	$497.37K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$568.88K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$599.30K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	500.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$11.30M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$9.08M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.28M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	5.14M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$3.02M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	7.49M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	5.14M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	7.49M	shares	Point-in-time
Deposits	`DepositsAssetsNoncurrent`	$95.08K	USD	Point-in-time
Deposits	`DepositsAssetsNoncurrent`	$95.04K	USD	Point-in-time
Goodwill	`Goodwill`	$285.39K	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$605.33K	USD	Point-in-time
Total Assets	`Assets`	$11.34M	USD	Point-in-time
Total Assets	`Assets`	$14.42M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.93M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$2.99M	USD	Point-in-time
Promissory notes payable-current portion	`NotesPayableToBankCurrent`	$329.30K	USD	Point-in-time
Secured convertible notes payable, net of debt issuance costs	`ConvertibleNotesPayableCurrent`	$1.50M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$281.00K	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$511.04K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$3.27M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$4.27M	USD	Point-in-time
Long term accrued liabilities	`AccountsPayableAndAccruedLiabilitiesNoncurrent`	$848.31K	USD	Point-in-time
Long term accrued liabilities	`AccountsPayableAndAccruedLiabilitiesNoncurrent`	$31.47K	USD	Point-in-time
Promissory notes payable-long term portion	`NotesPayableToBankNoncurrent`	$517.49K	USD	Point-in-time
Total liabilities	`Liabilities`	$5.63M	USD	Point-in-time
Total liabilities	`Liabilities`	$3.30M	USD	Point-in-time
Commitments and contingencies (Note K)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note K)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of September 30, 2021 and 2020, respectively	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of September 30, 2021 and 2020, respectively	`PreferredStockValue`	-	USD	Point-in-time
Common stock, par value $0.001 per share; 200,000,000 shares authorized as of September 30, 2021 and 2020, 7,486,120 and 5,142,779 shares issued and outstanding as of September 30, 2021 and 2020, respectively	`CommonStockValue`	$5.14K	USD	Point-in-time
Common stock, par value $0.001 per share; 200,000,000 shares authorized as of September 30, 2021 and 2020, 7,486,120 and 5,142,779 shares issued and outstanding as of September 30, 2021 and 2020, respectively	`CommonStockValue`	$7.49K	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapitalCommonStock`	$295.23M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapitalCommonStock`	$275.55M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-284.12M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-269.84M	USD	Point-in-time
Applied DNA Sciences, Inc. stockholders' equity:	`StockholdersEquity`	$11.11M	USD	Point-in-time
Applied DNA Sciences, Inc. stockholders' equity:	`StockholdersEquity`	$5.72M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$-722.00	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$-8.72K	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-848.50K	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$5.71M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.11M	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$11.34M	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$14.42M	USD	Point-in-time

Income Statement 43 line items

Line Item	Tag	Value	Unit	Period
Total revenues	`RevenueFromContractWithCustomerIncludingAssessedTax`	$9.03M	USD	Annual
Total revenues	`RevenueFromContractWithCustomerIncludingAssessedTax`	$1.93M	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$10.03M	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$12.61M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$3.32M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$3.77M	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$844.44K	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$285.73K	USD	Annual
Impairment losses	`GoodwillAndIntangibleAssetImpairment`	-	USD	Annual
Impairment losses	`GoodwillAndIntangibleAssetImpairment`	$821.74K	USD	Annual
Total operating expenses	`OperatingExpenses`	$18.04M	USD	Annual
Total operating expenses	`OperatingExpenses`	$13.64M	USD	Annual
LOSS FROM OPERATIONS	`OperatingIncomeLoss`	$-13.11M	USD	Annual
LOSS FROM OPERATIONS	`OperatingIncomeLoss`	$-12.53M	USD	Annual
Interest income (expense), net	`InterestIncomeExpenseNet`	$-115.83K	USD	Annual
Interest income (expense), net	`InterestIncomeExpenseNet`	$13.68K	USD	Annual
Loss on extinguishment of convertible notes payable	`GainsLossesOnExtinguishmentOfDebt`	$-1.77M	USD	Annual
Loss on extinguishment of convertible notes payable	`GainsLossesOnExtinguishmentOfDebt`	-	USD	Annual
Gain on extinguishment of notes payable	`GainLossOnExtinguishmentOfNotesPayablesCaresAct`	-	USD	Annual
Gain on extinguishment of notes payable	`GainLossOnExtinguishmentOfNotesPayablesCaresAct`	$839.95K	USD	Annual
Other expense, net	`OtherNonoperatingIncomeExpense`	$-243.58K	USD	Annual
Other expense, net	`OtherNonoperatingIncomeExpense`	$-378.07K	USD	Annual
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-14.28M	USD	Annual
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-13.03M	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	-	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	-	USD	Annual
NET LOSS	`ProfitLoss`	$-13.03M	USD	Annual
NET LOSS	`ProfitLoss`	$-14.28M	USD	Annual
Less: Net (income) loss attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-1.69K	USD	Annual
Less: Net (income) loss attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$8.00K	USD	Annual
NET LOSS attributable to Applied DNA Sciences, Inc.	`NetIncomeLoss`	$-14.29M	USD	Annual
NET LOSS attributable to Applied DNA Sciences, Inc.	`NetIncomeLoss`	$-13.03M	USD	Annual
Deemed dividend related to warrant modifications	`DeemedDividendRelatedToWarrantModifications`	$-2.84K	USD	Annual
NET LOSS attributable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-13.03M	USD	Annual
NET LOSS attributable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-14.29M	USD	Annual
Net loss per share attributable to common stockholders - basic	`EarningsPerShareBasic`	$-3.32	USD	Annual
Net loss per share attributable to common stockholders - basic	`EarningsPerShareBasic`	$-2.07	USD	Annual
Net loss per share attributable to common stockholders - diluted	`EarningsPerShareDiluted`	$-3.32	USD	Annual
Net loss per share attributable to common stockholders - diluted	`EarningsPerShareDiluted`	$-2.07	USD	Annual
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	6.92M	shares	Annual
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	3.92M	shares	Annual
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	6.92M	shares	Annual
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	3.92M	shares	Annual

Cash Flow Statement 71 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-13.03M	USD	Annual
Net loss	`ProfitLoss`	$-14.28M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$285.73K	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$844.44K	USD	Annual
Loss on disposal of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	-	USD	Annual
Loss on disposal of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	$-208.78K	USD	Annual
Impairment of goodwill and intangible assets	`GoodwillAndIntangibleAssetImpairment`	-	USD	Annual
Impairment of goodwill and intangible assets	`GoodwillAndIntangibleAssetImpairment`	$821.74K	USD	Annual
Loss on extinguishment of convertible notes payable	`GainsLossesOnExtinguishmentOfDebt`	$-1.77M	USD	Annual
Loss on extinguishment of convertible notes payable	`GainsLossesOnExtinguishmentOfDebt`	-	USD	Annual
Gain on extinguishment of notes payable	`GainLossOnExtinguishmentOfNotesPayablesCaresAct`	-	USD	Annual
Gain on extinguishment of notes payable	`GainLossOnExtinguishmentOfNotesPayablesCaresAct`	$839.95K	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$1.00M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$1.67M	USD	Annual
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	-	USD	Annual
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$26.02K	USD	Annual
Provision for bad debts	`ProvisionForDoubtfulAccounts`	$45.28K	USD	Annual
Provision for bad debts	`ProvisionForDoubtfulAccounts`	$28.63K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$2.64M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-600.35K	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$872.57K	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$354.74K	USD	Annual
Prepaid expenses and other current assets and deposits	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$27.29K	USD	Annual
Prepaid expenses and other current assets and deposits	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-30.41K	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$427.37K	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$94.71K	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenues`	$-117.96K	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenues`	$-230.04K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-13.39M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-11.14M	USD	Annual
Purchase of intangible asset	`PaymentsToAcquireIntangibleAssets`	-	USD	Annual
Purchase of intangible asset	`PaymentsToAcquireIntangibleAssets`	-	USD	Annual
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.06M	USD	Annual
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$2.55M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.06M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-2.55M	USD	Annual
Net proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$8.06M	USD	Annual
Net proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$2.61M	USD	Annual
Net proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$1.10M	USD	Point-in-time
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$13.76M	USD	Annual
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Net proceeds from sale of common stock and warrants	`NetProceedsFromSaleOfCommonStockAndWarrants`	$10.64M	USD	Annual
Net proceeds from sale of common stock and warrants	`NetProceedsFromSaleOfCommonStockAndWarrants`	-	USD	Annual
Repayment of convertible notes	`RepaymentsOfConvertibleDebt`	$1.67M	USD	Annual
Repayment of convertible notes	`RepaymentsOfConvertibleDebt`	$107.80K	USD	Annual
Proceeds from promissory notes	`ProceedsFromConvertibleDebt`	-	USD	Annual
Proceeds from promissory notes	`ProceedsFromConvertibleDebt`	$846.79K	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$14.70M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$19.43M	USD	Annual
Net increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$7.23M	USD	Annual
Net increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-1.23M	USD	Annual
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.55M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$7.79M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$558.99K	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.55M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$7.79M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$558.99K	USD	Point-in-time
Cash paid during period for interest	`InterestPaidNet`	$45.35K	USD	Annual
Cash paid during period for interest	`InterestPaidNet`	-	USD	Annual
Cash paid during period for income taxes	`IncomeTaxesPaid`	-	USD	Annual
Cash paid during period for income taxes	`IncomeTaxesPaid`	-	USD	Annual
Interest paid in kind	`PaidInKindInterest`	$28.33K	USD	Annual
Interest paid in kind	`PaidInKindInterest`	$35.62K	USD	Annual
Property and equipment acquired, and included in accounts payable	`PropertyPlantAndEquipmentAcquiredAndIncludedInAccountsPayable`	$181.81K	USD	Annual
Property and equipment acquired, and included in accounts payable	`PropertyPlantAndEquipmentAcquiredAndIncludedInAccountsPayable`	$144.03K	USD	Annual
Deemed dividend-warrant repricing	`DeemedDividendWarrantRepricing`	-	USD	Annual
Deemed dividend-warrant repricing	`DeemedDividendWarrantRepricing`	$2.84K	USD	Annual
Deferred offering costs reclassified to additional paid in capital	`ReclassificationOfDeferredOfferingCostToAdditionalPaidInCapital`	$109.70K	USD	Annual
Deferred offering costs reclassified to additional paid in capital	`ReclassificationOfDeferredOfferingCostToAdditionalPaidInCapital`	-	USD	Annual
Issuance of warrants in settlement of convertible notes payable	`IssuanceOfWarrantsInSettlementOfConvertibleNotesPayable`	$1.07M	USD	Annual
Issuance of warrants in settlement of convertible notes payable	`IssuanceOfWarrantsInSettlementOfConvertibleNotesPayable`	-	USD	Annual

Stockholders Equity 19 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-848.50K	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$5.71M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.11M	USD	Point-in-time
Balance (in shares)	`CommonStockSharesOutstanding`	5.14M	shares	Point-in-time
Balance (in shares)	`CommonStockSharesOutstanding`	7.49M	shares	Point-in-time
Common stock issued in public offering, net of offering costs	`SharesIssuedInPublicOffering`	$-13.76M	USD	Annual
Common stock issued in public offering, net of offering costs	`SharesIssuedInPublicOffering`	$-10.53M	USD	Annual
Exercise of warrants	`StockIssuedDuringPeriodValueWarrantsExercised`	$2.61M	USD	Annual
Exercise of warrants	`StockIssuedDuringPeriodValueWarrantsExercised`	$8.06M	USD	Annual
Fair value of warrants issued in connection with convertible note repayment	`WarrantsIssuedDuringPeriodValueWarrants`	$1.64M	USD	Annual
Stock based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$1.00M	USD	Annual
Stock based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$1.67M	USD	Annual
Net loss	`ProfitLoss`	$-13.03M	USD	Annual
Net loss	`ProfitLoss`	$-14.28M	USD	Annual
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-848.50K	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$5.71M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.11M	USD	Point-in-time
Balance (in shares)	`CommonStockSharesOutstanding`	5.14M	shares	Point-in-time
Balance (in shares)	`CommonStockSharesOutstanding`	7.49M	shares	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.